<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="165506">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943306</url>
  </required_header>
  <id_info>
    <org_study_id>733-012</org_study_id>
    <nct_id>NCT00943306</nct_id>
  </id_info>
  <brief_title>Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long term follow on study to assess the continued long term safety and efficacy of
      lomitapide in patients with homozygous familial hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III open label clinical trial to evaluate the long-term efficacy and safety
      of lomitapide at the maximum tolerated dose (for each patient) established during the
      clinical trial 733-005/UP1002. Subjects completing study 733-005/UP1002 who have not met any
      of the stopping criteria will be eligible to participate in 733-012. The treatment period
      will continue until a decision has been made by the local competent authority regarding
      marketing authorization. Lomitapide will be given orally once daily. Patient specific doses
      will be carried forward from 733-005/UP1002, but will not exceed the maximum tolerated dose
      the patient received during 733-005 /UP1002. The maximum dose for any patient is 80 mg/day.
      There is no reference therapy in this trial. The effects of the study drug will be compared
      to baseline data (from 733-005/UP1002). Concomitant lipid-lowering therapy including
      plasmapheresis or LDL apheresis is permitted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in LDL-C</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in lipid parameters</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term safety</measure>
    <time_frame>Every 12 weeks until the study is completed</time_frame>
    <description>This is an open ended study that will continue until a local market authorization decision is made in each region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent hepatic fat by NMRS</measure>
    <time_frame>Every 24 weeks until the study is completed</time_frame>
    <description>This is an open ended study that will remain open until a local decision regarding market authorization is made</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>lomitapide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated dose of lomitapide (up to 80mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <description>5-60 mg po every day</description>
    <arm_group_label>lomitapide</arm_group_label>
    <other_name>AEGR-733</other_name>
    <other_name>BMS-201038</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed UP1002 or 733-005.

          2. Willing and able to provide consent and comply with the requirements of the study
             protocol.

        Exclusion Criteria:

          1. Met any of the stopping rules for study discontinuation at the final visit of study
             UP1002 or 733-005.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Sumeray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aegerion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic and University of Montreal Community Genomic Medicine Center</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Interna Universitaria</name>
      <address>
        <city>Ferrara</city>
        <state>Sicily</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Delle Patologie Emergenti</name>
      <address>
        <city>Palermo</city>
        <state>Sicily</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Universitario Dislipidemie</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Capetown</name>
      <address>
        <city>Cape town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148-56.</citation>
    <PMID>17215532</PMID>
  </reference>
  <reference>
    <citation>Cuchel M, Meagher E, Marais AD, et.al. Abstract 1077: A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide (AEGR-733) in patients with homozygous familial hypercholesterolemia: interim results at 6 months. Circulation, Nov 2009; 120: S441</citation>
  </reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 26, 2015</lastchanged_date>
  <firstreceived_date>July 21, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Homozygous</keyword>
  <keyword>Familial</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>MTP</keyword>
  <keyword>Apheresis</keyword>
  <keyword>lomitapide</keyword>
  <keyword>Homozygous Familial Hypercholesterolemia (HoFH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
